Merger and acquisition (M&A) deals, including asset purchases, recorded a decrease in the number of deals and deal values in Q2 2015 with 276 deals worth USD101.6 billion, compared to 303 deals worth USD160.5 billion in Q2 2014. On a quarter-on-quarter basis, the number of deals and their values increased in Q2 2015, compared to 247 deals worth USD100.9 billion in Q1 2015.
The central nervous system therapeutics market accounted for the majority of M&As with 176 deals worth USD299.8 billion between Q2 2014 and Q2 2015. Oncology therapeutics market followed in second place with 174 deals worth USD304.4 billion.
Deal Value Of Partnerships Increased In Q2 2015
Partnerships reported an increase in the number of deals and deal values with 285 deals worth USD8.5 billion in Q2 2015, compared to 179 deals worth USD5.1 billion in Q2 2014. On a quarter-on-quarter basis, the number of partnerships and their values increased in Q2 2015, compared to 204 deals worth USD7.7 billion in Q1 2015.
Pharmaceutical and healthcare companies entered into 85 partnerships for Preclinical stage products, which accounted for 29% of the deals from Q2 2014 to Q2 2015. Products in Marketed stage stood second with 60 deals, which accounted for 21% of the deals.
The oncology therapeutics market stood at the top in the pharmaceutical and healthcare industry with 268 partnerships worth USD13.6 billion between Q2 2014 and Q2 2015. The central nervous system therapeutics market followed with 104 deals worth USD3.3 billion in the same period.
